Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine


Flink H. J. , Hansen B. E. , Heathcote E. J. , Feinman S. V. , Simsek H. , Karayalcin S., ...Daha Fazla

AMERICAN JOURNAL OF GASTROENTEROLOGY, cilt.101, sa.11, ss.2523-2529, 2006 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 101 Konu: 11
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1111/j.1572-0241.2006.00812.x
  • Dergi Adı: AMERICAN JOURNAL OF GASTROENTEROLOGY
  • Sayfa Sayıları: ss.2523-2529

Özet

OBJECTIVES: Antiviral therapy leads to HBeAg seroconversion in 10-40% of the patients with HBeAg-positive chronic hepatitis B. Nonresponse may result in progression of liver disease and increased risk of hepatocellular carcinoma. As part of a global randomized controlled trial we investigated the efficacy (i.e., loss of HBeAg at the end of follow-up) of peginterferon alfa-2b (Peg-IFN alpha 2b) in patients who failed to respond to previous courses of standard interferon (IFN) or lamivudine.